Vivos Therapeutics, Inc. VVOS revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Vivos Therapeutics, Inc. reported revenue across 10 products and services; the largest, Service, was $11M (+53.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Service$11Mshare n/a+53.1% yoy
- Product$6.49Mshare n/a-17.6% yoy
- Sleep Testing Services$6.04Mshare n/a+371.2% yoy
- Appliances$3.28Mshare n/a-41.5% yoy
- Tooth Positioners$3.21Mshare n/a+41.2% yoy
- Treatment Centers$2.18Mshare n/ano prior
- Sponsorship Seminar Other$1.22Mshare n/a-37.0% yoy
- Billing Intelligence Services$686Kshare n/a-18.3% yoy
- +2 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Service$3.7Mshare n/a+207.6% yoy
- Sleep Testing Services$2.3Mshare n/a+610.8% yoy
- Product$1.44Mshare n/a-20.6% yoy
- Tooth Positioners$1.02Mshare n/a+88.5% yoy
- Treatment Centers$892Kshare n/ano prior
- Appliances$422Kshare n/a-66.8% yoy
- +4 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.